Experience of using a complex bioregulatory drug in young children

Abstract

Introduction. The paper presents modern insights into the pathogenesis and role of inflammatory reactions in the development

of the respiratory pathology. The safety and high potential of the use of complex bioregulatory drugs as elements of pathogenetic and symptomatic therapy of the respiratory diseases have been substantiated. The authors present the results of their own clinical observations on the use of a complex bioregulatory drug as an anti-inflammatory agent to treat acute respiratory diseases in young children.

Clinical case 1. The observation included 102 children aged 1 to 3 years with the symptoms of acute respiratory viral infection, who underwent outpatient treatment. 53 children of them received a complex bioregulatory drug as a symptomatic antiinflammatory and antipyretic therapy according to the treatment regimen set out in the patient information leaflet. The comparison group consisted of 49 children, who received acetaminophen derivatives to relieve the similar symptoms at least once per day. The findings showed that the bioregulatory drug, when used according to the treatment regimen, effectively relieved the symptoms of fever in 46 children (87%), the same indicator in the comparison group was 44 children (89%) (p > 0.05%).

Clinical case 2.We observed 26 children aged 9 to 18 months with teething syndrome, which was treated with a bioregulatory drug as a symptomatic therapy. The therapy lasted 3 to 7 days. The results showed that the bioregulatory drug effectively relieved the whole complex of teething symptoms.

Сonclusion. Viburcol has been shown to be highly effective as an antipyretic agent, as well as a drug to relieve symptoms during teething. No children who used the drug showed side effects. The authors advise the widespread use of complex bioregulatory drugs in routine paediatric practice.